A Randomized, Double-Blind, Placebo-Controlled Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DC739 Multiple-Dose in Hypercholesterolemic Subjects.
Latest Information Update: 21 Mar 2022
At a glance
- Drugs DC 371739 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Guangzhou JOYO Pharma
Most Recent Events
- 15 Mar 2022 Status changed from recruiting to completed.
- 21 Jun 2021 New trial record